Fuji completes cell culture manufacturing expansion in U.K.

Fujifilm Diosynth Biotechnologies in Texas
Fujifilm Diosynth Biotechnologies has completed a 10,000-square-foot expansion of its cell culture manufacturing facility in the U.K.

In April, Fujifilm Diosynth Biotechnologies outlined $130 million in projects it had undertaken to build up a biologics CMO business, and this week it said one of those projects is ready.

The Japanese company has opened its $9 million, 10,000-square-foot, cell culture process development laboratories in Billingham, U.K., which will support its monoclonal antibody (mAb) platform for cell culture development work.

RELATED: Fujifilm invests $116M in U.S. as it races competitors for biologics contract work

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The company this spring completed a $93 million Texas manufacturing facility it picked up several years ago in its buyout of College Station, Texas-based Kalon Biotherapeutics. Kalon's facilities include high containment manufacturing and a cell culture capacity of 6,000 liters that can be expanded to 24,000 liters in upstream capacity.  

Fuji in April said that it intended to invest another $23 million to expand the Texas manufacturing facility. 

All of this is with the goal of hitting about $1 billion in biologics contract work by 2023 as Fuji races competitors to capture the burgeoning biologics CDMO business.

Suggested Articles

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.